Key Highlights from the Report:

· Global Clinical Trial Expansion:
-Over 1,500 drug candidates in development across phases 0 to III.
-CAR-T therapies account for 32% of the pipeline, primarily targeting hematological cancers.
-The global trial landscape experienced a 32.5% growth from 2019 to 2023, with Asia-Pacific leading in trial activity (44% of all trials).
· Oncology Focus:
-CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and hematological malignancies.
-Significant attention on gastrointestinal tract and lung cancers, as well as hematological cancers like diffuse large B-cell lymphoma (DLBCL).
· Geographic Leadership:
-Asia-Pacific: Strong growth driven by China, which leads with 56% of the region's cell and gene trials.
-North America: The U.S. dominates with 85% of the trials.
-Europe: The UK, Spain, and Germany are key players.
· Technological Advancements:
-AI and Contract Development and Manufacturing Organizations (CDMOs) are transforming the cell and gene therapy landscape, improving manufacturing efficiency and trial scalability.
· Patient Recruitment Trends:
-Faster recruitment in Asia-Pacific (16.07 months) compared to the U.S. (21.15 months), with the region showing higher enrollment efficiency.
· Investment Growth:
-A significant rise in venture capital for cell and gene therapies peaked in 2021, with sustained funding for start-ups and growth-stage companies.

Novotech’s whitepaper highlights the significant potential of cell and gene therapies, particularly in oncology, and outlines opportunities for increased collaboration in global clinical trials.